HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Koichiro Kuwahara Selected Research

Nitrendipine

1/2016Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure.
10/2014Inhibition of N-type Ca2+ channels ameliorates an imbalance in cardiac autonomic nerve activity and prevents lethal arrhythmias in mice with heart failure.
9/2009T-type Ca2+ channel blockade prevents sudden death in mice with heart failure.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Koichiro Kuwahara Research Topics

Disease

42Heart Failure
12/2022 - 05/2003
13Myocardial Infarction
12/2022 - 05/2003
10Cardiomegaly (Heart Hypertrophy)
12/2013 - 10/2003
9Hypertrophy
12/2013 - 02/2002
8Stroke (Strokes)
12/2022 - 01/2016
8Fibrosis (Cirrhosis)
12/2016 - 10/2003
6Peripheral Arterial Disease
12/2022 - 11/2017
5Cardiovascular Diseases (Cardiovascular Disease)
12/2021 - 03/2011
5Coronary Artery Disease (Coronary Atherosclerosis)
08/2021 - 01/2017
4Chronic Limb-Threatening Ischemia
11/2022 - 01/2019
4Atrial Fibrillation
07/2022 - 09/2017
4Cardiomyopathies (Cardiomyopathy)
12/2019 - 05/2007
4Cardiac Arrhythmias (Arrythmia)
01/2019 - 03/2006
4Sudden Death
01/2016 - 06/2009
4Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
10/2014 - 06/2009
3Diabetes Mellitus
07/2022 - 01/2020
3Chronic Renal Insufficiency
01/2022 - 01/2016
3Infections
11/2021 - 01/2021
3Inflammation (Inflammations)
02/2021 - 01/2017
3Left Ventricular Dysfunction
06/2017 - 11/2005
2Frailty
12/2022 - 12/2021
2Anemia
11/2021 - 08/2021
2Acute Coronary Syndrome
11/2021 - 02/2021
2Thrombosis (Thrombus)
07/2021 - 01/2019
2Hemorrhage
03/2021 - 01/2018
2Amyloidosis
01/2021 - 12/2019
2Body Weight (Weight, Body)
01/2021 - 08/2009
2Ischemia
08/2020 - 01/2003
2Ventricular Tachycardia
01/2020 - 05/2013
2Hypokalemia
07/2019 - 11/2016
2Death (Near-Death Experience)
02/2019 - 10/2014
2Atherosclerosis
01/2019 - 01/2017
2Infarction (Infarctions)
11/2018 - 05/2003
2Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
02/2018 - 03/2006
2Diabetic Nephropathies (Diabetic Nephropathy)
01/2017 - 01/2016
2Hypertension (High Blood Pressure)
11/2016 - 05/2012
2Chronic Kidney Failure (Chronic Renal Failure)
01/2014 - 01/2012
2Heart Diseases (Heart Disease)
01/2013 - 01/2010
1Sleep Initiation and Maintenance Disorders (Insomnia)
10/2022
1Arteriovenous Fistula
07/2022
1Venous Thrombosis (Deep-Vein Thrombosis)
07/2022
1ST Elevation Myocardial Infarction
07/2022
1Endocarditis
05/2022
1Pneumonia (Pneumonitis)
05/2022
1Abscess
05/2022
1Hyperuricemia
01/2022

Drug/Important Bio-Agent (IBA)

21Brain Natriuretic Peptide (Natrecor)FDA Link
01/2022 - 02/2002
10Atrial Natriuretic Factor (ANF)IBA
11/2021 - 10/2003
10Angiotensin IIIBA
01/2020 - 05/2003
5Natriuretic PeptidesIBA
10/2022 - 08/2005
5pro-brain natriuretic peptide (1-76)IBA
11/2021 - 01/2012
5Biomarkers (Surrogate Marker)IBA
05/2021 - 06/2013
5Type 1 Angiotensin ReceptorIBA
01/2016 - 03/2006
4AlbuminsIBA
07/2022 - 01/2017
4omega-Chloroacetophenone (Mace)IBA
10/2021 - 01/2016
4Hormones (Hormone)IBA
02/2018 - 02/2002
4RE1-silencing transcription factorIBA
05/2013 - 12/2006
3Anti-Bacterial Agents (Antibiotics)IBA
05/2022 - 10/2018
3Hemoglobins (Hemoglobin)IBA
08/2021 - 01/2016
3Pharmaceutical PreparationsIBA
02/2021 - 03/2006
3Transcription Factors (Transcription Factor)IBA
01/2019 - 12/2006
3cilnidipineIBA
11/2018 - 10/2014
3NitrendipineIBA
01/2016 - 09/2009
3Messenger RNA (mRNA)IBA
09/2015 - 05/2003
3Guanylate Cyclase-Coupled ReceptorsIBA
08/2009 - 10/2003
3atrial natriuretic factor receptor AIBA
06/2009 - 02/2004
2Proteins (Proteins, Gene)FDA Link
01/2022 - 01/2005
2Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA
11/2021 - 02/2019
2CreatinineIBA
08/2021 - 01/2016
2Serum AlbuminIBA
08/2021 - 01/2020
2Sodium-Glucose Transporter 2 InhibitorsIBA
10/2020 - 01/2020
2Mineralocorticoid Receptor AntagonistsIBA
10/2020 - 01/2019
2empagliflozinIBA
10/2020 - 01/2020
2SodiumIBA
01/2020 - 08/2005
2CatecholaminesIBA
11/2019 - 10/2018
2Hyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsIBA
07/2019 - 02/2007
2Apolipoproteins E (ApoE)IBA
01/2019 - 11/2012
2myocardinIBA
01/2019 - 07/2010
2Antihypertensive Agents (Antihypertensives)IBA
11/2016 - 08/2009
2Peptides (Polypeptides)IBA
01/2014 - 06/2013
2CollagenIBA
07/2010 - 08/2009
2TRPC6 Cation ChannelIBA
06/2010 - 12/2006
2CalcineurinIBA
06/2010 - 12/2006
2CytokinesIBA
11/2005 - 01/2005
1DiureticsIBA
10/2022
1AnticoagulantsIBA
07/2022
1Vitamin KFDA Link
07/2022
1Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA
05/2022
1Cilostazol (Pletal)FDA LinkGeneric
01/2022
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2022
1LipidsIBA
01/2022

Therapy/Procedure

11Therapeutics
12/2022 - 05/2012
6Surgical Amputation (Amputations)
12/2022 - 01/2018
5Percutaneous Coronary Intervention
10/2021 - 11/2017
4Renal Dialysis (Hemodialysis)
07/2022 - 01/2014
3Catheter Ablation
02/2021 - 01/2019
2Stents
07/2022 - 07/2021
2Length of Stay
11/2021 - 01/2021
1Limb Salvage
11/2022
1Polypharmacy
01/2022